CD70 and nonpapillary renal cell carcinoma: A dual-targeted fine-tuned immune-restoring CAR-T for ccRCC, aimed at both CAIX and CD70, and engineered to co-release immune checkpoint inhibitors, is currently under preclinical assessment (106).